MCID: NDL007
MIFTS: 48

Nodular Goiter

Categories: Endocrine diseases

Aliases & Classifications for Nodular Goiter

MalaCards integrated aliases for Nodular Goiter:

Name: Nodular Goiter 12 15 17 70
Goiter, Nodular 12 44
Non-Toxic Nodular Goiter 70
Nodular Goitre 12
Goiter Nodular 54

Classifications:



External Ids:

Disease Ontology 12 DOID:13197
MeSH 44 D006044
NCIt 50 C131437
SNOMED-CT 67 237570007
UMLS 70 C0018023 C1318500

Summaries for Nodular Goiter

MalaCards based summary : Nodular Goiter, also known as goiter, nodular, is related to plummer's disease and hyperthyroidism. An important gene associated with Nodular Goiter is TG (Thyroglobulin), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Remifentanil and Caffeine have been mentioned in the context of this disorder. Affiliated tissues include thyroid, bone and skin, and related phenotypes are growth/size/body region and homeostasis/metabolism

Wikipedia : 73 Nodular goiter is an enlarged thyroid gland with bumps (nodules) on it. It is associated with both high... more...

Related Diseases for Nodular Goiter

Diseases related to Nodular Goiter via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 394)
# Related Disease Score Top Affiliating Genes
1 plummer's disease 32.2 TSHR TPO TG ICAM1
2 hyperthyroidism 31.4 TSHR TPO TG CTLA4 CRP CALCA
3 goiter 30.9 VEGFA TSHR TPO TG SLC5A5 RET
4 graves disease 1 30.7 TSHR TPO TG SLC5A5 CALCA
5 adenoma 30.7 TSHR TG RET LGALS3 BRAF
6 endemic goiter 30.6 TSHR TPO TG CALCA
7 postsurgical hypothyroidism 30.5 TPO TG
8 nontoxic goiter 30.5 TSHR TPO TG CALCA
9 toxic diffuse goiter 30.4 TSHR TPO TG
10 parathyroid adenoma 30.4 VEGFA RET LGALS3 CALCA
11 hypoparathyroidism 30.3 TPO RET CTLA4 CALCA
12 thyroid carcinoma 30.3 TSHR TPO TG SLC5A5 RET LGALS3
13 substernal goiter 30.3 TG CALCA
14 thyroid gland medullary carcinoma 30.3 TG RET KDR CALCA
15 fetal adenoma 30.2 TG CALCA
16 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.2 TSHR TPO TG CTLA4
17 graves' disease 30.2 TSHR TPO TG ICAM1 FAS CTLA4
18 thyroid carcinoma, familial medullary 30.1 TG RET CALCA BRAF
19 thyroid tumor 30.1 RET BRAF
20 myxedema 30.0 TSHR TPO TG CTLA4
21 congenital hypothyroidism 30.0 TSHR TPO TG SLC5A5
22 pendred syndrome 30.0 TPO TG SLC5A5
23 angina pectoris 29.9 IL6 ICAM1 CRP
24 thyroiditis 29.9 TSHR TPO TG RET IL6 CTLA4
25 subacute thyroiditis 29.9 TSHR TPO TG IL6 CRP
26 vascular dementia 29.8 VEGFA IL6 ICAM1 CRP
27 multinodular goiter 29.7 VEGFA TSHR TPO TG KRT19 HRAS
28 gastroenteritis 29.7 IL6 CRP CALCA
29 hypothyroidism 29.6 TSHR TPO TG SLC5A5 RET LGALS3
30 lung disease 29.5 VEGFA RET IL6 ICAM1 CRP
31 thyroid gland disease 29.4 TSHR TPO TG SLC5A5 RET LGALS3
32 papillary carcinoma 29.4 TSHR TPO TG RET LGALS3 KRT19
33 suppurative thyroiditis 29.3 TSHR TPO TG SLC5A5 KRT19 CRP
34 exanthem 29.2 VEGFA IL6 HRAS CTLA4 CRP
35 eye disease 29.2 VEGFA TSHR LGALS3 KDR IL6 ICAM1
36 neuroendocrine tumor 29.2 VEGFA RET KRT19 HRAS CALCA
37 autoimmune disease 29.1 TSHR TPO TNFRSF4 TG IL6 FAS
38 differentiated thyroid carcinoma 29.0 VEGFA TSHR TPO TG RET HRAS
39 type 2 diabetes mellitus 28.7 VEGFA LGALS3 KDR IL6 ICAM1 HGF
40 follicular adenoma 28.4 TSHR TPO TG RET LGALS3 KRT19
41 diabetes mellitus 27.9 VEGFA TPO TG LGALS3 KDR IL6
42 renal cell carcinoma, nonpapillary 27.7 VEGFA RET KRT19 KDR ICAM1 HRAS
43 thyroid gland follicular carcinoma 27.6 VEGFA TSHR TPO TG SLC5A5 RET
44 thyroid gland cancer 27.6 VEGFA TSHR TPO TG SLC5A5 RET
45 hashimoto thyroiditis 27.3 TSHR TPO TG RET LGALS3 KRT19
46 thyroid cancer, nonmedullary, 1 10.5
47 mechanical strabismus 10.4 TPO TG
48 thyrotoxic exophthalmos 10.4 TG IL6
49 endocrine exophthalmos 10.4 TG IL6
50 osteosclerotic myeloma 10.4 VEGFA IL6

Comorbidity relations with Nodular Goiter via Phenotypic Disease Network (PDN):


Goiter Hypertension, Essential
Hypothyroidism

Graphical network of the top 20 diseases related to Nodular Goiter:



Diseases related to Nodular Goiter

Symptoms & Phenotypes for Nodular Goiter

MGI Mouse Phenotypes related to Nodular Goiter:

46 (show all 24)
# Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 10.48 BRAF FAS HGF HRAS ICAM1 IL6
2 homeostasis/metabolism MP:0005376 10.48 BRAF CRP CTLA4 FAS HRAS ICAM1
3 cellular MP:0005384 10.45 BRAF FAS HGF ICAM1 IL6 KDR
4 immune system MP:0005387 10.44 BRAF CRP CTLA4 FAS ICAM1 IL6
5 behavior/neurological MP:0005386 10.43 BRAF FAS HGF HRAS IL6 KDR
6 endocrine/exocrine gland MP:0005379 10.43 BRAF CTLA4 FAS HRAS ICAM1 IL6
7 hematopoietic system MP:0005397 10.43 BRAF CTLA4 FAS HGF ICAM1 IL6
8 cardiovascular system MP:0005385 10.42 BRAF CRP CTLA4 FAS HGF HRAS
9 mortality/aging MP:0010768 10.38 BRAF CTLA4 FAS HGF HRAS ICAM1
10 digestive/alimentary MP:0005381 10.37 BRAF CTLA4 FAS HRAS ICAM1 IL6
11 integument MP:0010771 10.34 BRAF CTLA4 FAS HRAS ICAM1 IL6
12 nervous system MP:0003631 10.22 BRAF FAS HGF HRAS ICAM1 IL6
13 craniofacial MP:0005382 10.2 BRAF FAS HRAS KDR KRT19 TNFRSF9
14 liver/biliary system MP:0005370 10.19 BRAF CTLA4 FAS HGF IL6 KDR
15 neoplasm MP:0002006 10.13 BRAF FAS HRAS ICAM1 IL6 KRT19
16 hearing/vestibular/ear MP:0005377 10.11 BRAF FAS HGF SLC5A5 TNFRSF9 TPO
17 muscle MP:0005369 10.06 BRAF FAS HRAS ICAM1 IL6 KDR
18 limbs/digits/tail MP:0005371 10.05 BRAF FAS RET TG TPO TSHR
19 normal MP:0002873 9.97 BRAF CTLA4 FAS HRAS KDR KRT19
20 no phenotypic analysis MP:0003012 9.91 HGF HRAS KDR KRT19 RET TNFRSF9
21 respiratory system MP:0005388 9.9 BRAF CTLA4 FAS HRAS IL6 KDR
22 renal/urinary system MP:0005367 9.86 BRAF FAS HRAS IL6 LGALS3 RET
23 skeleton MP:0005390 9.83 BRAF CTLA4 FAS HGF HRAS IL6
24 vision/eye MP:0005391 9.32 BRAF FAS ICAM1 IL6 KDR SLC5A5

Drugs & Therapeutics for Nodular Goiter

Drugs for Nodular Goiter (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 35)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Remifentanil Approved Phase 4 132875-61-7 60815
2
Caffeine Approved Phase 4 58-08-2 2519
3
Methimazole Approved Phase 4 60-56-0 1349907
4
Iodine Approved, Investigational Phase 4 7553-56-2 807
5
Cadexomer iodine Experimental Phase 4 94820-09-4
6 Narcotics Phase 4
7 Analgesics, Opioid Phase 4
8 Analgesics Phase 4
9 Antirheumatic Agents Phase 4
10 Anti-Inflammatory Agents Phase 4
11 Mesalamine Phase 4 89-57-6
12 Calcium Supplement Phase 4
13 Calcium, Dietary Phase 4
14 Anti-Inflammatory Agents, Non-Steroidal Phase 4
15 Analgesics, Non-Narcotic Phase 4
16 Hormones Phase 4
17 Hormone Antagonists Phase 4
18 Antithyroid Agents Phase 4
19 Trace Elements Phase 4
20 Anti-Infective Agents, Local Phase 4
21 Nutrients Phase 4
22 Micronutrients Phase 4
23 Anti-Infective Agents Phase 4
24
Calcium Nutraceutical Phase 4 7440-70-2 271
25
Bupivacaine Approved, Investigational 38396-39-3, 2180-92-9 2474
26
Vincristine Approved, Investigational 2068-78-2, 57-22-7 5978
27
Doxorubicin Approved, Investigational 23214-92-8 31703
28
Cyclophosphamide Approved, Investigational 50-18-0, 6055-19-2 2907
29
Dactinomycin Approved, Investigational 50-76-0 2019 457193
30
Ifosfamide Approved 3778-73-2 3690
31 Anesthetics
32 Liver Extracts
33 Anesthetics, Local
34
Isophosphamide mustard 100427
35
Liposomal doxorubicin 31703

Interventional clinical trials:

(show all 20)
# Name Status NCT ID Phase Drugs
1 Comparison of Different Doses of Remifentanil on Postoperative Pain in Patients Undergoing Thyroidectomy: a Prospective, Double-blinded Randomized Control Trial Unknown status NCT01761149 Phase 4 Remifentanil
2 CLINICAL MANAGEMENT OF CHILDHOOD INTESTINAL LYMPHOID NODULAR HYPERPLASIA: A RANDOMIZED CONTROLLED CLINICAL TRIAL. Unknown status NCT01789294 Phase 4 Mesalamine
3 The Influence of Continuous Treatment With Antithyroid Drugs on the Effect of Radioiodine in Patients With Hyperthyroidism Completed NCT00150137 Phase 4 Methimazole
4 The Influence of Continuous Block-replacement Therapy on the Effect of Radioiodine in Patients With Hyperthyroidism Completed NCT00150124 Phase 4 MTZ+LT4;Methimazole
5 TSH-adapted Therapy in a Large Randomized, Observer-blind, Placebo-controlled, Prospective Treatment Study of Patients With Nodular Goiter Completed NCT00277589 Phase 4 Levothyroxin-Na;Levothyroxine-Na + iodide;Iodide;Placebo
6 The Effect of 0.1 mg Recombinant Human Thyrotropin (rhTSH) on Thyroid Radioiodine-uptake and the Degree of Goiter Reduction Following 131I-therapy, in Patients With Benign Non-toxic Nodular Goiter. A Randomized, Double-blind, Placebo-controlled Trial. Completed NCT00275171 Phase 2 Recombinant human thyrotropin (Thyrogen);recombinant human TSH
7 Pretreatment With Recombinant Human Thyrotropin (rhTSH) for the Effect on Thyroid Size and Function, and for the Effect of Radioiodine Treatment in Patients With Nodular Goiter. Prospective, Randomized Double-blinded Trials. Completed NCT00145366 Phase 2 Recombinant human thyrotropin (Thyrogen)
8 Contrast Enhanced Ultrasound for the Evaluation of Focal Liver Lesions - a Multi-center Study on the Usefulness in the Clinical Practice Unknown status NCT01329458
9 Changes in Esophageal Motility and Swallowing Symptoms After Thyroid Surgery - a Prospective Cohort Study Unknown status NCT03100357
10 Thyroidectomy Improves Tracheal Anatomy and Airflow in Patients With Nodular Goiter: A Prospective Cohort Study Completed NCT03072654
11 Accuracy of Ultrasound Elastastography in Thyroid Nodular Disease. Completed NCT01102127
12 Levothyroxine Treatment in Thyroid Benign Nodular Goiter Completed NCT00552253 Levothyroxin treatment
13 Randomized Placebo Controlled Clinical Study of Anethum Graveolens L. (Dill) in Thyroiditis and Nodular Goiter Patients Completed NCT04482907
14 Diagnosis Interest of Galectin 3 Dosage in Nodular and Multinodular Goiter Pretreatment Completed NCT01588288
15 Pilot Study on Laser Ablation of Symptomatic Benign Thyroid Masses Completed NCT00615537
16 "The Fingerprint: Spoke-wheel Sign" of Focal Nodular Hyperplasia: Assessment of Novel Ultrasound Approach Using Superb Microvascular Imaging Technique Completed NCT02737865 Sonazoid
17 A Randomized Control Trial Comparing Bilateral Superficial Cervical Plexus Block and Local Wound Infiltration in Thyroidectomy and Parathyroidectomy Completed NCT02205801 0.9% saline;Marcaine
18 Quantitative Real-time Ultrasound Elastography (Shear Wave Elastography - SWE™) for Characterisation of Liver Tumors Completed NCT02156700
19 Delta Neutrophil Index and Neutrophil Lymphocyte Ratio in Differentiation of Thyroid Malignancy and Nodular Goiter Completed NCT04425512
20 International Pleuropulmonary Blastoma Registry for PPB, DICER1 and Associated Conditions Recruiting NCT03382158

Search NIH Clinical Center for Nodular Goiter

Cochrane evidence based reviews: goiter, nodular

Genetic Tests for Nodular Goiter

Anatomical Context for Nodular Goiter

MalaCards organs/tissues related to Nodular Goiter:

40
Thyroid, Bone, Skin, Lymph Node, Lung, Neutrophil, Kidney

Publications for Nodular Goiter

Articles related to Nodular Goiter:

(show top 50) (show all 1763)
# Title Authors PMID Year
1
[Transcription and promoter hypermethylation of thyroid stimulating hormone receptor gene in human papillary thyroid carcinoma]. 54 61
20117998 2010
2
Congenital hypothyroidism and late-onset goiter: identification and characterization of a novel mutation in the sodium/iodide symporter of the proband and family members. 61 54
19916865 2009
3
[Expressions of RASSF1A, Galectin-3 and TPO mRNA in papillary thyroid carcinoma and their clinical significance]. 54 61
19799084 2009
4
H-RAS gene expression in human multinodular goiter. 54 61
17290351 2007
5
Isthmus-preserving total bilobectomy: an adequate operation for C-cell hyperplasia. 54 61
16680601 2006
6
Analysis of costimulatory molecules OX40/4-1BB (CD134/CD137) detection on chosen mononuclear cells in children and adolescents with Graves' disease during methimazole therapy. 54 61
16459462 2005
7
[Expression and significance of VEGF, VEGF-C, and VEGF-D in papillary thyroid carcinoma]. 61 54
16159441 2005
8
[Relationship between OX40/4-1 BB (CD134/CD137) costimulatory molecules expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease]. 54 61
16232366 2005
9
Relationship between CTLA-4 and CD28 molecule expression on T lymphocytes and stimulating and blocking autoantibodies to the TSH-receptor in children with Graves' disease. 61 54
16220002 2005
10
Increased thymidine kinase activity in human thyroid toxic adenomas: effects of exposure to epidermal growth factor in vitro. 61 54
15098918 2004
11
Medullary thyroid carcinoma. 61 54
15658665 2004
12
Calcitonin measurement to detect medullary thyroid carcinoma in nodular goiter: German evidence-based consensus recommendation. 61 54
14758572 2004
13
[Analysis of costimulatory molecules (CD28-CTLA-4/B7) expression on chosen mononuclear cells in adolescents with Graves' disease during methimazole therapy]. 61 54
15504312 2004
14
[Expression of cytokeratins and ret in thyroid papillary carcinoma]. 54 61
14761598 2003
15
[Correlation between serum thyroglobulin and thyroid stimulating hormone in populations with non-toxic goiter]. 61 54
12899791 2003
16
Expression of very late antigen-4 and lymphocyte function-associated antigen-1 on peripheral blood lymphocytes from patients with graves disease. 61 54
12357047 2002
17
[Expression of TTF-1 in thyroid tumors originating from follicular epithelium and its correlation with expression of RET, galectin-3 and mucin-1 genes]. 61 54
11953175 2002
18
Serum levels of cytokines in children and adolescents with Graves' disease and non-toxic nodular goiter. 54 61
11453524 2001
19
[Impact of serum thyroglobulin concentration in the diagnosis of benign and malignant thyroid diseases]. 54 61
10984889 2000
20
Serum levels of the cytokines IL-1beta, IL-6 and ICAM-1 after 131I-treatment of Graves' disease and nodular goiter. 61 54
10965935 2000
21
Concordance of eight kits for antithyroid peroxidase autoantibodies determination. 54 61
10987206 2000
22
Evaluation of routine basal serum calcitonin measurement for early diagnosis of medullary thyroid carcinoma in seven hundred seventy-three patients with nodular goiter. 61 54
10411120 1999
23
Role of serum thyroglobulin in the pre-operative evaluation of follicular thyroid tumours. 54 61
9870733 1998
24
Post-thyroidectomy hypocalcemia: the role of calcitonin, parathormone and serum albumin. 54 61
9239811 1996
25
Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. 61 54
7677193 1995
26
Activation of T lymphocyte subsets by synthetic TSH receptor peptides and recombinant glutamate decarboxylase in autoimmune thyroid disease and insulin-dependent diabetes. 54 61
7714099 1995
27
T-cells recognize multiple epitopes in the human thyrotropin receptor extracellular domain. 54 61
7533773 1995
28
Reduced activation of suppressor T lymphocytes by specific antigens in autoimmune thyroid disease. 61 54
8258649 1993
29
Serum thyroglobulin level in patients with diffuse and nodular goiter, after therapeutic application of stable iodine. 54 61
1628693 1992
30
Lack of response of peripheral blood mononuclear cells to thyroid microsomal antigen in nontoxic nodular goiters. 54 61
2121217 1990
31
Patient outcomes following surgical management of thyroid nodules classified as Bethesda category III (AUS/FLUS). 61
33749812 2021
32
Effectiveness of hemi-thyroidectomy in relieving compressive symptoms in cases with large multi nodular goiter. 61
33786164 2021
33
Incidence of thyroid disorders in the second decade of adequate iodine supply in Slovenia. 61
32377868 2021
34
Clinical, sonographical, and pathological findings of pediatric thyroid nodules. 61
33772338 2021
35
Basal and stimulated calcitonin for the diagnosis of medullary thyroid cancer: updated thresholds and safety assessment. 61
32656666 2021
36
Delta Neutrophil Index and Neutrophil-to-Lymphocyte Ratio in the Differentiation of Thyroid Malignancy and Nodular Goiter. 61
33067685 2021
37
Impact of Radioiodine Treatment on Doppler Flow Parameters in the Central Retinal Artery and Ophthalmic Artery in Patients With Hyperthyroidism. 61
32697397 2021
38
Single-cell transcriptomic landscape reveals the differences in cell differentiation and immune microenvironment of papillary thyroid carcinoma between genders. 61
33588924 2021
39
The Role of Nuclear Medicine in the Clinical Management of Benign Thyroid Disorders. Part 2. Nodular Goiter, Hypothyroidism, and Subacute Thyroiditis. 61
33579801 2021
40
Differences in the dielectric properties of various benign and malignant thyroid nodules. 61
33119125 2021
41
Correlations of HOTAIR expression with pathological stage, CT characteristics and prognosis of patients with papillary thyroid carcinoma. 61
33721460 2021
42
Relationship between urinary metabolites of polycyclic aromatic hydrocarbons and risk of papillary thyroid carcinoma and nodular goiter: A case-control study in non-occupational populations. 61
33310200 2021
43
Thiocyanate in excess develops goiter followed by auto immune thyroid diseases even after effective salt iodization in a rural community of north east India. 61
33396042 2021
44
Multiple ectopic goiter in the retroperitoneum, abdominal wall, liver, and diaphragm: A case report and review of literature. 61
33344620 2020
45
Positive Thyroid Peroxidase Antibody and Thyroglobulin Antibody are Associated With Better Clinicopathologic Features of Papillary Thyroid Cancer. 61
33645517 2020
46
nPAsym: an open-source plugin for ImageJ to quantify nuclear shape asymmetry. 61
32544781 2020
47
Ultrasonographic characteristics of thyroid metastasis from clear cell renal cell carcinoma: A case report. 61
33157967 2020
48
Diagnostic value of circulating cell-free mtDNA in patients with suspected thyroid cancer: ND4/ND1 ratio as a new potential plasma marker. 61
33035689 2020
49
Adenomatous hyperplastic intratracheal ectopic thyroid tissue: a case report. 61
33213237 2020
50
[Clinical application of the gasless unilateral axillary approach in endoscopic thyroid surgery]. 61
33036505 2020

Variations for Nodular Goiter

Expression for Nodular Goiter

Search GEO for disease gene expression data for Nodular Goiter.

Pathways for Nodular Goiter

Pathways related to Nodular Goiter according to GeneCards Suite gene sharing:

(show all 38)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.98 VEGFA TNFRSF9 TNFRSF4 RET LGALS3 IL6
2
Show member pathways
13.79 VEGFA TNFRSF9 TNFRSF4 KDR IL6 HRAS
3
Show member pathways
13.26 TNFRSF9 TNFRSF4 KDR IL6 HRAS HGF
4
Show member pathways
13.22 VEGFA TNFRSF9 TNFRSF4 RET IL6 ICAM1
5
Show member pathways
12.95 VEGFA KDR IL6 HRAS HGF FAS
6
Show member pathways
12.85 TSHR TPO TG SLC5A5 HRAS BRAF
7
Show member pathways
12.7 VEGFA KDR HRAS HGF BRAF
8 12.7 VEGFA RET IL6 HRAS HGF FAS
9 12.68 VEGFA KDR HRAS HGF FAS BRAF
10
Show member pathways
12.56 TNFRSF9 IL6 HRAS FAS CTLA4
11 12.52 TNFRSF9 TNFRSF4 LGALS3 FAS CTLA4
12
Show member pathways
12.36 KDR IL6 HRAS HGF BRAF
13 12.35 VEGFA RET KDR HGF
14
Show member pathways
12.34 VEGFA KDR IL6 HRAS HGF BRAF
15
Show member pathways
12.33 VEGFA KDR ICAM1 HRAS BRAF
16
Show member pathways
12.3 VEGFA TSHR TPO TG IL6 ICAM1
17 11.94 VEGFA KDR HRAS HGF FAS BRAF
18 11.93 VEGFA IL6 ICAM1 HGF
19 11.86 VEGFA IL6 ICAM1 HRAS
20 11.84 VEGFA KRT19 KDR IL6 HGF
21 11.79 VEGFA IL6 ICAM1 CTLA4
22
Show member pathways
11.77 TNFRSF9 TNFRSF4 FAS
23
Show member pathways
11.73 RET KDR HRAS BRAF
24 11.7 VEGFA HRAS BRAF
25 11.67 TSHR HRAS BRAF
26 11.63 VEGFA HRAS HGF BRAF
27
Show member pathways
11.62 VEGFA IL6 ICAM1
28 11.62 IL6 HGF CALCA
29
Show member pathways
11.6 TNFRSF9 TNFRSF4 BRAF
30 11.6 TNFRSF4 IL6 ICAM1 CTLA4
31 11.5 IL6 ICAM1 HGF
32 11.48 VEGFA RET HRAS
33 11.35 VEGFA TPO IL6 HGF
34 11.34 IL6 ICAM1 FAS
35 11.32 VEGFA KDR HGF
36
Show member pathways
11.23 VEGFA HRAS CRP
37 11.19 VEGFA KDR HRAS BRAF
38 9.7 TSHR TPO TG SLC5A5

GO Terms for Nodular Goiter

Cellular components related to Nodular Goiter according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.86 TSHR TPO TNFRSF9 TNFRSF4 RET KDR
2 extracellular space GO:0005615 9.81 VEGFA TPO TG LGALS3 IL6 ICAM1
3 plasma membrane GO:0005886 9.8 TSHR TPO TNFRSF9 TNFRSF4 SLC5A5 RET
4 external side of plasma membrane GO:0009897 9.72 TNFRSF9 TNFRSF4 ICAM1 FAS CTLA4
5 membrane raft GO:0045121 9.67 RET KDR ICAM1 FAS
6 cell surface GO:0009986 9.17 VEGFA TSHR TPO TNFRSF4 LGALS3 ICAM1

Biological processes related to Nodular Goiter according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.91 VEGFA KDR IL6 HGF FAS BRAF
2 positive regulation of gene expression GO:0010628 9.88 VEGFA RET IL6 HRAS CRP BRAF
3 positive regulation of cell migration GO:0030335 9.77 VEGFA RET KDR HRAS HGF
4 positive chemotaxis GO:0050918 9.7 VEGFA LGALS3 HGF
5 monocyte chemotaxis GO:0002548 9.69 LGALS3 IL6 CALCA
6 negative regulation of extrinsic apoptotic signaling pathway via death domain receptors GO:1902042 9.65 ICAM1 HGF FAS
7 positive regulation of ERK1 and ERK2 cascade GO:0070374 9.65 VEGFA KDR ICAM1 HRAS BRAF
8 negative regulation of endothelial cell apoptotic process GO:2000352 9.63 KDR ICAM1 BRAF
9 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.62 VEGFA IL6 ICAM1 HGF
10 hormone biosynthetic process GO:0042446 9.58 TPO TG
11 negative regulation of lipid storage GO:0010888 9.57 IL6 CRP
12 vascular wound healing GO:0061042 9.56 VEGFA KDR
13 positive regulation of endothelial cell chemotaxis by VEGF-activated vascular endothelial growth factor receptor signaling pathway GO:0038033 9.55 VEGFA KDR
14 positive regulation of protein phosphorylation GO:0001934 9.55 VEGFA KDR HRAS HGF FAS
15 vascular endothelial growth factor receptor-2 signaling pathway GO:0036324 9.54 VEGFA KDR
16 iodide transport GO:0015705 9.49 TG SLC5A5
17 thyroid hormone generation GO:0006590 9.13 TPO TG SLC5A5
18 positive regulation of MAPK cascade GO:0043410 9.02 VEGFA RET KDR IL6 HRAS

Molecular functions related to Nodular Goiter according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.86 VEGFA TG KDR HGF FAS CRP
2 signaling receptor activity GO:0038023 9.35 TSHR TNFRSF9 RET ICAM1 FAS
3 chemoattractant activity GO:0042056 9.33 VEGFA LGALS3 HGF
4 tumor necrosis factor-activated receptor activity GO:0005031 9.32 TNFRSF4 FAS
5 protein-containing complex binding GO:0044877 9.17 TSHR KRT19 ICAM1 HRAS HGF CALCA

Sources for Nodular Goiter

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....